We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05041127
Recruitment Status : Recruiting
First Posted : September 10, 2021
Last Update Posted : December 7, 2022
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
This is a multicenter, single arm, phase 2 study designed to evaluate the efficacy and safety of cetuximab for the treatment of advanced (unresectable)/metastatic, chordoma. The target patient population will be any chordoma patient 18 years of age with locally unresectable disease or metastatic disease.

Condition or disease Intervention/treatment Phase
Chordoma Metastatic Chordoma Unresectable Chordoma Biological: Cetuximab Other: Questionnaire Administration Phase 2

Detailed Description:

Primary Objective:

• To evaluate the efficacy of cetuximab in patients with advanced (unresectable) or metastatic, chordoma based on response rate according to RECIST1.1.

Secondary Objectives:

  • To evaluate response rate according to Choi criteria
  • To evaluate the safety and tolerability of cetuximab for chordoma patients
  • To evaluate the progression-free survival (median, at 24 weeks, and 52 weeks) and to determine the overall survival (median).
  • To evaluate the ratio of PFS on study compared to PFS from prior treatment

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Cetuximab for Patients With Advanced or Metastatic Chordoma
Actual Study Start Date : May 27, 2022
Estimated Primary Completion Date : September 1, 2024
Estimated Study Completion Date : September 1, 2024

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Chordoma
Drug Information available for: Cetuximab

Arm Intervention/treatment
Experimental: Treatment (cetuximab)
Patients receive cetuximab IV over 60-120 minutes QW in the absence of disease progression or unacceptable toxicity.
Biological: Cetuximab
Given IV
Other Names:
  • Cetuximab Biosimilar CDP-1
  • Cetuximab Biosimilar CMAB009
  • Cetuximab Biosimilar KL 140
  • Chimeric Anti-EGFR Monoclonal Antibody
  • Chimeric MoAb C225
  • Chimeric Monoclonal Antibody C225
  • Erbitux
  • IMC-C225

Other: Questionnaire Administration
Ancillary studies

Primary Outcome Measures :
  1. Overall response rate [ Time Frame: through study completion, an average of 1 year ]
    Measured by Response Evaluation Criteria in Solid Tumors 1.1. Will be estimated based on a binomial portion expressed as percentage with 95% confidence intervals.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years
  • Histologically confirmed diagnosis of chordoma which is advanced (unresectable) and/or metastatic
  • ECOG Performance Status of ≤ 2
  • At least one site of measurable disease on x-ray/CT/MRI and/or PET/CT scan as defined by RECIST 1.1 criteria. Baseline imaging must be performed within 30 days of Day 1 of study.
  • Adequate organ function within 28 days of Day 1 of study defined as:
  • The patient has adequate hematologic function, as evidenced by an absolute neutrophil count (ANC) ≥ 1000/L, hemoglobin ≥ 9 g/dL (5.58 mmol/L), and platelets ≥ 100,000/L
  • The patient has adequate hepatic function as defined by a total bilirubin ≤1.5 mg/dL (25.65 μmol/L) (NOTE: Patients with elevated bilirubin secondary to Gilbert's disease are eligible to participate in the study), and aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.0 times the upper limit of normal (ULN; or 5.0 times the ULN in the setting of liver metastases).

The patient has adequate renal function as defined by a serum creatinine ≤1.5 times the ULN, or creatinine clearance (measured via 24-hour urine collection) ≥40 mL/minute (that is, if serum creatinine is >1.5 times the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed).

  • Patients may have any prior line of therapy, but there should a washout period of at least 3 weeks from any systemic therapy (small molecule/targeted agents, immunotherapies) and/or radiation therapy.
  • Patients should be completely recovered from any reversible toxicities associated with any prior therapies.
  • There should be access of archival tumor tissue for central pathology review, or a new tumor related biopsy should be considered within acceptable risk to the patient.
  • Patients must have no prior history of use of an EGFR inhibitor for treatment of their chordoma
  • Because the teratogenicity of cetuximab is not known, the patient, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Women of childbearing potential must have a negative serum pregnancy test ≤ seven days prior to Day 1 of study.
  • Life expectancy of > 3 months

Exclusion Criteria:

  • Prior use of an EGFR inhibitor for treatment of their chordoma
  • Non-metastatic, resectable disease
  • No measurable disease according to RECIST 1.1
  • Life expectancy of less than 3 months
  • Other invasive malignancy within 2 years except for noninvasive malignancies such as cervical carcinoma in situ, non-melanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that has/have been surgically cured.
  • Concomitant participation to another clinical trial with active agent during the study (concomitant non-interventional study will be allowed) Patients who have a history of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab, red meat allergy, or tick bite history
  • Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol
  • The patient has clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months or high risk of uncontrolled arrhythmia or uncontrolled cardiac insufficiency.
  • The patient has uncontrolled or poorly-controlled hypertension (>180 mmHg systolic or > 130 mmHg diastolic.
  • Major surgery within 4 weeks prior to Day 1 of study or who have not recovered adequately from prior surgery
  • Patients who have received wide field radiotherapy ≤ 3 weeks or limited field radiation for palliation < 3 weeks prior to Day 1 of study or who have not recovered adequately from side effects of such therapy
  • Patients who have received any prior systemic therapy < 3 weeks prior to Day 1 of study or have not recovered adequately from toxicities to the baseline.
  • Women who are pregnant or nursing/breastfeeding.
  • Inability to comply with protocol required procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05041127

Layout table for location contacts
Contact: Anthony Conley, MD 713-796-3626 aconley@mdanderson.org

Layout table for location information
United States, Texas
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Anthony P. Conley, MD    713-796-3626    aconley@mdanderson.org   
Principal Investigator: Anthony P. Conley, MD         
Sponsors and Collaborators
M.D. Anderson Cancer Center
Layout table for investigator information
Principal Investigator: Anthony P Conley, MD M.D. Anderson Cancer Center
Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT05041127    
Other Study ID Numbers: 2020-0217
NCI-2020-14259 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2020-0217 ( Other Identifier: M D Anderson Cancer Center )
First Posted: September 10, 2021    Key Record Dates
Last Update Posted: December 7, 2022
Last Verified: November 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Antineoplastic Agents, Immunological
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents